Ulinastatin attenuates pulmonary endothelial glycocalyx damage and inhibits endothelial heparanase activity in LPS-induced ARDS

Biochemical and Biophysical Research Communications

Volumn 478, Issue 2, 2016, Pages 669-675

  Wang, Lipeng ^a   Huang, Xiao ^a   Kong, Guiqing ^a   Xu, Haixiao ^a   Li, Jiankui ^a   Hao, Dong ^a   Wang, Tao ^a   Han, Shasha ^a   Han, Chunlei ^a   Sun, Yeying ^a   Liu, Xiangyong ^a   Wang, Xiaozhi ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Acute respiratory distress syndrome (ARDS); Endothelial glycocalyx; Heparanase (HPA); Lysosome; Ulinastatin (UTI)

Indexed keywords

HEPARANASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; ULINASTATIN; BETA GLUCURONIDASE; GLYCOPROTEIN; HEPARAN SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; GLYCOCALYX; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG EDEMA; LUNG ENDOTHELIUM; LYSOSOME; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; RAT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL SURVIVAL; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM; ENZYMOLOGY; GENETICS; LUNG; METABOLISM; PATHOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPILLARY PERMEABILITY; CELL SURVIVAL; ENDOTHELIUM; GENE EXPRESSION; GLUCURONIDASE; GLYCOCALYX; GLYCOPROTEINS; HEPARITIN SULFATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; LUNG; LYSOSOMES; MALE; MICE; MICE, INBRED C57BL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84992743784     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.08.005     Document Type: Article

References (32)

1. [1] Ware, L.B., Matthay, M.A., The acute respiratory distress syndrome. N. Enql J. Med. 342 (2000), 1334–1349.
2. [2] Short, K.R., Kroeze, E.J., Fouchier, R.A., Kuiken, T., Pathogenesis of infl uenza-induced acute respiratory distress syndrome. Lancet Infect. Dis. 14 (2014), 57–69.
3. [3] Mammoto, A., Mammoto, T., Kanapathipillai, M., Wing, C.Y., Jiang, E., Jiang, A., Lofgren, K., Gee, E.P., Ingber, D.E., Control of lung vascular permeability and endotoxin-induced pulmonary edema by changes in extracellular matrix mechanics. Nat. Commun., 4, 2013, 1759.
4. [4] Lennon, F.E., Singleton, P.A., Hyaluronan regulation of vascular integrity. Am. J. Cardiovasc Dis. 1 (2011), 200–213.
5. [5] Becker, B.F., Chappell, D., Jacob, M., Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res. Cardiol. 105 (2010), 687–701.
6. [6] Kolářová, H., Ambrůzová, B., Šindlerová, L., Svihálková, Klinke, A., Kubala, L., Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediat. Inflamm., 2014, 694312.
7. [7] Pries, A.R., Secomb, T.W., Gaehtgens, P., The endothelial surface layer. Pflugers Arch. 440 (2014), 653–666.
8. [8] Barakat, A.I., Dragging along: the glycocalyx and vascular endothelial cell mechano transduction. Circ. Res. 102 (2008), 747–748.
9. [9] Fu, B.M., Tarbell, J.M., Mechano-sensing and transduction by endothelial surface glycocalyx: composition, structure, and function. Wiley Interdiscip. Rev. Syst. Biol. Med. 5 (2013), 381–390.
10. [10] Reitsma, S., Slaaf, D.W., Vink, H., Zandvoort, M.A., van, M.G., Egbrink, Oude, The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 454 (2007), 345–359.
11. [11] Tarbell, J.M., Pahakis, M.Y., Mechanotransduction and the glycocalyx. J. Intern Med. 259 (2006), 339–350.
12. [12] Chappell, D., Jacob, M., Rehm, M., Stoeckelhuber, M., Welsch, U., Conzen, P., Becker, B.F., Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx. Biol. Chem. 389 (2008), 79–82.
13. [13] Cohen, E., Atzmon, R., Vlodavsky, I., Ilan, N., Heparanase processing by lysosomal/endosomal protein preparation. FEBS Lett. 579 (2005), 2334–2338.
14. [14] Zetser, A., Levy-Adam, F., Kaplan, v., Gingis-Velitski, S., Bashenko, Y., Schubert, S., Flugelman, M.Y., Vlodavsky, I., Ilan, N., Processing and activation of latent heparanase occurs in lysosomes. J. Cell Sci. 117 (2004), 2249–2258.
15. [15] Linder, A., Russell, J.A., An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med. 40 (2014), 1164–1167.
16. [16] Pugia, M.J., Lott, J.A., Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clin. Chem. Lab. Med. 43 (2005), 1–16.
17. [17] Uemura, K., Murakami, Y., Hayashidani, Y., Sudo, T., Hashimoto, Y., Ohge, H., Sueda, T., Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy. J. Surg. Oncol. 98 (2008), 309–313.
18. [18] Nakatani, K., Takeshita, S., Tsujimoto, H., Kawamura, Y., Sekine, I., Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J. Leukoc. Biol. 69 (2001), 241–247.
19. [19] Inoue, K., Takano, H., Shimada, A., Yanagisawa, R., Sakurai, M., Yoshino, S., Sato, H., Yoshikawa, T., Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol. Pharmacol. 67 (2005), 673–680.
20. [20] Fang, Y., Xu, P., Gu, C., Wang, Y., Fu, X.J., Yu, W.R., Yao, M., Ulinastatin improves pulmonary function in severe burn-induced acute lung injury by attenuating inflammatory response. J. Trauma 71 (2011), 1297–1304.
21. [21] Nishina, K., Mikawa, K., Takao, Y., et al. ONO-5046, an elastase inhitor, attenuates endotoxin-indced acute lung injury in rabbits. Anesth. Analq 84 (1997), 1097–1103.
22. [22] Peng, X., Hassoun, P.M., Sammani, S., McVerry, B.J., Burne, M.J., Rabb, H., Pearse, D., Tuder, R.M., Garcia, J.G., Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 169 (2004), 1245–1251.
23. [23] Kong, G.Q., Huang, X., Wang, L.P., Li, Y., Sun, T., Han, S.S., Zhu, W.W., Ma, M.M., Tian, H.H., Xu, H.X., Li, J.K., Zhang, X.H., Liu, X.Y., Wang, X.Z., Astilbin alleviates LPS-induced ARDS by suppressing MAPK signaling pathway and protecting pulmonary endothelial glycocalyx. Int. Immunopharmacol. 36 (2016), 51–58.
24. [24] Burke-Gaffney, A., Evans, T.W., Lest we forget the endothelial glycocalyx in sepsis. Crit. Care, 16, 2012, 121.
25. [25] Johansson, P.I., Stensballe, J., Rasmussen, L.S., Ostrowski, S.R., A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann. Surg. 254 (2011), 194–200.
26. [26] Myburgh, J.A., Mythen, M.G., Resuscitation fluids. N. Engl. J. Med. 369 (2013), 1243–1251.
27. [27] Nelson, A., Berkestedt, I., Schmidtchen, A., Ljunggren, L., Bodelsson, M., Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock 30 (2008), 623–627.
28. [28] Steppan, J., Hofer, S., Funke, B., Brenner, T., Henrich, M., Martin, E., et al. Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalix. J. Surg. Res. 165 (2011), 136–141.
29. [29] Godder, K., Vlodavsky, I., Eldor, A., Weksler, B.B., Haimovitz-Freidman, A., Fuks, Z., Heparanase activity in cultured endothelial cells. J. Cell Physiol. 148 (1991), 274–280.
30. [30] Nakajima, M., Irimura, T., Nicolson, G.L., A solid-phase substrate of heparanase: its application to assay of human melanoma for heparan sulfate degradative activity. Anal. Biochem. 157 (1986), 162–171.
31. [31] Schmidt, E.P., Yang, Y., Janssen, W.J., et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat. Med. 18 (2012), 1217–1223.
32. [32] Pillay, C.S., Elliott, E., Dennison, C., Endolysosomal proteolysis and its regulation. Biochem. J. 363 (2002), 417–429.